IL325421A - טיפול משולב - Google Patents

טיפול משולב

Info

Publication number
IL325421A
IL325421A IL325421A IL32542125A IL325421A IL 325421 A IL325421 A IL 325421A IL 325421 A IL325421 A IL 325421A IL 32542125 A IL32542125 A IL 32542125A IL 325421 A IL325421 A IL 325421A
Authority
IL
Israel
Prior art keywords
combined treatment
treatment
combined
Prior art date
Application number
IL325421A
Other languages
English (en)
Inventor
Vladimir Razinkov
Greg Barnett
Ayodeji Abdur-Rasheed Asuni
Berit Olsen Krogh
Mark Byron Kneller
Original Assignee
H Lundbeck As
Vladimir Razinkov
Greg Barnett
Asuni Ayodeji Abdur Rasheed
Berit Olsen Krogh
Mark Byron Kneller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As, Vladimir Razinkov, Greg Barnett, Asuni Ayodeji Abdur Rasheed, Berit Olsen Krogh, Mark Byron Kneller filed Critical H Lundbeck As
Publication of IL325421A publication Critical patent/IL325421A/he

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL325421A 2023-06-23 2025-12-18 טיפול משולב IL325421A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363509854P 2023-06-23 2023-06-23
PCT/IB2024/056106 WO2024261733A1 (en) 2023-06-23 2024-06-21 Combinational treatment

Publications (1)

Publication Number Publication Date
IL325421A true IL325421A (he) 2026-02-01

Family

ID=91946676

Family Applications (1)

Application Number Title Priority Date Filing Date
IL325421A IL325421A (he) 2023-06-23 2025-12-18 טיפול משולב

Country Status (12)

Country Link
EP (1) EP4731664A1 (he)
KR (1) KR20260030117A (he)
CN (1) CN121358766A (he)
AU (1) AU2024313073A1 (he)
CL (1) CL2025003405A1 (he)
CO (1) CO2025014681A2 (he)
CR (1) CR20250530A (he)
DO (1) DOP2025000251A (he)
IL (1) IL325421A (he)
JO (1) JOP20250314A1 (he)
MX (1) MX2025015461A (he)
WO (1) WO2024261733A1 (he)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5766883A (en) 1989-04-29 1998-06-16 Delta Biotechnology Limited Polypeptides
FR2650598B1 (fr) 1989-08-03 1994-06-03 Rhone Poulenc Sante Derives de l'albumine a fonction therapeutique
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
AU3272695A (en) 1994-08-12 1996-03-07 Immunomedics Inc. Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
US6653104B2 (en) 1996-10-17 2003-11-25 Immunomedics, Inc. Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
EP1583550A2 (en) 2003-01-16 2005-10-12 D. Collen Research Foundation vzw Inhibition of pacap signalling for the prevention and treatment of thrombocytopenia
TW201531484A (zh) 2007-05-21 2015-08-16 Alder Biopharmaceuticals Inc 抗ＴＮＦ-α之抗體及其用途
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
CA2730615A1 (en) 2008-07-18 2010-01-21 Galderma Research & Development Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
WO2012106407A2 (en) 2011-02-01 2012-08-09 The University Of Vermont And State Agricultural College Diagnostic and therapeutic methods and products related to anxiety disorders
CA3020839A1 (en) 2016-04-15 2017-10-19 Alder Biopharmaceuticals, Inc. Anti-pacap antibodies and uses thereof
WO2023042123A1 (en) * 2021-09-15 2023-03-23 H. Lundbeck A/S Anti-cgrp antibody dosing and screening methods

Also Published As

Publication number Publication date
CO2025014681A2 (es) 2025-10-30
EP4731664A1 (en) 2026-04-29
DOP2025000251A (es) 2025-11-16
AU2024313073A1 (en) 2026-02-12
MX2025015461A (es) 2026-02-03
CL2025003405A1 (es) 2026-01-23
WO2024261733A1 (en) 2024-12-26
KR20260030117A (ko) 2026-03-05
JOP20250314A1 (ar) 2025-12-16
CN121358766A (zh) 2026-01-16
CR20250530A (es) 2026-01-12

Similar Documents

Publication Publication Date Title
IL285771A (he) טיפול ברלאקורילנט
EP4493175A4 (en) MIRDAMETINIB TREATMENT
JP1789691S (ja) 皮膚治療機器
EP4382023A4 (en) Endoscope
EP4391884A4 (en) ENDOSCOPE
IL308335A (he) טיפולים משולבים
EP4312708A4 (en) ENDOSCOPE
JP1708791S (ja) マッサージ器
JP1778652S (ja) マッサージ器
EP4398893A4 (en) IBOGAINE COMBINATION THERAPY
EP4405465A4 (en) TREATMENT METHODS
EP4502348A4 (en) TREATMENT DEVICE
EP4401721A4 (en) CANCER TREATMENT
IL288237A (he) טיפול משולב
EP4174556A4 (en) Endoscope
EP4396225A4 (en) METHOD OF TREATMENT
IL313079A (he) שיטות טיפול באמצעות lou064
EP4527285A4 (en) ENDOSCOPE
EP4464233A4 (en) Endoscope
EP4337181A4 (en) COMBINED TREATMENT PROCESSES
EP4509324A4 (en) TREATMENT SOLUTION
JP1778600S (ja) マッサージ器
JP1779429S (ja) マッサージ器
JP1779324S (ja) マッサージ器
JP1769908S (ja) マッサージ器